Edgewise Therapeutics (EWTX) Financials

Edgewise Therapeutics (NASDAQ:EWTX) remains a development-stage biotechnology company with no reported revenue. Total revenue has been zero in every quarter provided, while operating expenses have increased steadily. Quarterly operating expenses rose from $18.3 million in Q3 2022 to $61.9 million in Q2 2026, driven primarily by research and development spending.

The company’s operating losses have also widened. Net loss increased from $17.5 million in Q3 2022 to $57.3 million in Q2 2026. The latest quarterly loss was larger than the $49.0 million loss in Q1 2026 and the $50.2 million loss in Q4 2025, although the Q2 operating cash burn of $42.5 million was slightly better than the $42.5 million recorded in Q1.

Edgewise continues to benefit from a substantial liquidity position. Cash and short-term investments totaled approximately $460.7 million at June 30, 2026, compared with $603.3 million a year earlier and $583.5 million at September 30, 2025. The balance sheet remains lightly leveraged, with total liabilities of $31.6 million against $448.1 million of equity.

• Strong liquidity: Cash and short-term investments of $460.7 million provide a significant funding base for clinical development and general operations.
• Limited debt burden: Total liabilities were only $31.6 million, and the statements show no meaningful debt repayment requirements in the latest periods.
• Interest income provides support: Interest and investment income contributed $4.6 million in Q2 2026, partially offsetting the company’s operating loss.
• Quarterly cash burn has been relatively stable recently: Operating cash outflows were $38.6 million in Q4 2025, $42.5 million in Q1 2026 and $42.5 million in Q2 2026, suggesting the recent burn rate has not accelerated materially from Q1.
• Investment activity is substantial but largely treasury management: The company recorded $131.6 million of investment maturities or sales and $53.1 million of investment purchases in Q2 2026, producing $78.5 million of investing cash inflow. This improved reported cash during the quarter but does not represent operating profitability.
• Research spending is increasing: Research and development expense reached $47.5 million in Q2 2026, up from $19.6 million in Q1 2023. This may support pipeline advancement, but the financial benefit depends on successful clinical and regulatory outcomes.
• Capital spending remains modest: Property, plant and equipment purchases were only $32,000 in Q2 2026, indicating that cash needs are primarily related to research, development and corporate activities rather than heavy infrastructure investment.
• No revenue has been reported: Edgewise has generated zero revenue in each income statement provided, leaving the company dependent on financing, investment income and its existing cash balance.
• Losses and operating expenses continue to expand: Q2 2026 operating expenses of $61.9 million were 11% higher than Q1 2026 and 36% higher than Q2 2025. Net loss attributable to common shareholders reached $57.6 million, or $0.53 per share.
• Shareholder dilution is a continuing risk: Weighted-average basic shares increased from 63.5 million in Q3 2023 to 107.7 million in Q2 2026. The company raised $188.2 million through financing activities in Q2 2025, while more recent financing inflows have been comparatively small.

At the recent Q2 2026 operating cash-burn rate of roughly $42 million per quarter, the company’s cash and short-term investments could theoretically support several years of operations before considering future changes in spending, investment income, clinical costs or capital raises. However, the declining liquidity balance, widening losses, lack of revenue and rising share count remain important risks for investors. The company’s financial outlook is therefore closely tied to whether its research programs can eventually produce commercially viable products.